A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Yu, Evan Y.
Yazji, Salim
Katz, Yisrael
Coates, Elisabeth
Nordquist, Luke T.
Vandross, Andrae Lavon
Salkeni, Mohamad Adham
Lang, Joshua Michael
Nelson, Peter
Breitmeyer, James Bradley
Fong, Lawrence
De Bono, Johann S.
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Oncternal Therapeut Inc, San Diego, CA USA
[3] Urol Canc Ctr PC, Omaha, NE USA
[4] NEXT Oncol, Austin, TX USA
[5] NEXT Oncol, Fairfax, VA USA
[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[7] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA USA
[8] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-225-3248-4005; 283-183-180-5577-2829-12292; 613-225-325; 261-436; 130-540-543; 283-183-180; 298-145-222-184-1022-9124; 7; 5; 4; 3; 2; 60; 2946; 1917; 162; 1; 38092-18135; 38092-18313; 38092-21759; 9;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS241 / TPS241
页数：1
相关论文
共 50 条
  • [41] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer
    Narayan, Vivek
    Patel, Miraj Y.
    Teitsson, Siguroli
    Rosenblatt, Lisa
    Yin, Xin
    Pivneva, Irina
    Gao, Sophie
    Sundar, Manasvi
    Betts, Keith A.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [43] The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
    Naiki, Taku
    Takahara, Kiyoshi
    Watanabe, Hiromitsu
    Nakane, Keita
    Sugiyama, Yosuke
    Koie, Takuya
    Shiroki, Ryoichi
    Miyake, Hideaki
    Yasui, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 164 - 171
  • [44] CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer
    Smith, Matthew Raymond
    Piulats, Josep M.
    Todenhofer, Tilman
    Lee, Jae-Lyun
    Arija, Jose Angel Arranz
    Mazilu, Laura
    Azad, Arun
    Alonso-Gordoa, Teresa
    McGovern, Ursula Brigid
    Choudhury, Atish Dipankar
    Ye, Dingwei
    Suzuki, Hiroyoshi
    Mckay, Rana R.
    Ades, Steven
    Flechon, Aude
    Pieczonka, Christopher Michael
    Hulstijn, Maarten
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [46] PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
    Sartor, A. Oliver
    Morris, Michael J.
    Chi, Kim N.
    De Bono, Johann S.
    Shore, Neal D.
    Crosby, Michael
    Kreisl, Teri Nguyen
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Influence of Statins on Survival Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Inhibitors
    Henriquez Lopez, I.
    Gomez, J.
    Torres, L.
    Acosta, J.
    Arquez, M.
    LaFuerza, A.
    Martinez, F.
    Miranda, M.
    Arenas, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E278 - E279
  • [48] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Luber, Brandon
    Wang, Hao
    Chen, Yan
    Nakazawa, Mary
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    JAMA ONCOLOGY, 2015, 1 (05) : 582 - 591
  • [49] Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kostos, Louise
    Tran, Ben
    Azad, Arun A.
    DRUGS, 2024, 84 (09) : 1093 - 1109
  • [50] A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Stewart, Tyler F.
    Gao, Xin
    Berghorn, Elmer
    Lu, Haolan
    Chan, Edward
    Gedrich, Richard
    Lang, Joshua Michael
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345